Cargando…
Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial
INTRODUCTION: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been shown to have beneficial effects on various cardiovascular (CV) outcomes in patients with type 2 diabetes (T2D) in primary prevention and in those with a high CV risk profile. However, the mechanism(s) responsible for these...
Autores principales: | Sorice, Gian Pio, Cinti, Francesca, Leccisotti, Lucia, D’Amario, Domenico, Lorusso, Margherita, Guzzardi, Maria Angela, Mezza, Teresa, Cocchi, Camilla, Capece, Umberto, Ferraro, Pietro Manuel, Crea, Filippo, Giordano, Alessandro, Iozzo, Patricia, Giaccari, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266960/ https://www.ncbi.nlm.nih.gov/pubmed/34037951 http://dx.doi.org/10.1007/s13300-021-01083-1 |
Ejemplares similares
-
Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report
por: Leccisotti, Lucia, et al.
Publicado: (2022) -
Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
por: Cinti, Francesca, et al.
Publicado: (2017) -
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
por: Cefalo, Chiara Maria Assunta, et al.
Publicado: (2019) -
Galectin-3 gene deletion results in defective adipose tissue maturation and impaired insulin sensitivity and glucose homeostasis
por: Blasetti Fantauzzi, Claudia, et al.
Publicado: (2020) -
The Interplay between Immune System and Microbiota in Diabetes
por: Moffa, Simona, et al.
Publicado: (2019)